JAMA Psychiatry
September 2, 2026
Diana K. Orsini, Sara Di Luch, George Tomlinson et al.
Importance Antidepressant efficacy of intravenous (IV) ketamine has been demonstrated in major depressive disorder; however, the efficacy and safety of ketamine for bipolar depression remain largely unknown, with limited data available in this specific population. Objective To evaluate the efficacy, safety, and tolerability of adjunctive IV ketamine compared with midazolam for...
Drug safety
September 2, 2026
You Wang, Alexandra S Storaci, G Caleb Alexander et al.
Treatment-resistant depression (TRD) is associated with elevated suicide risk, but real-world evidence on whether esketamine reduces suicide attempts and intentional self-harm remains limited. The aim was to estimate whether current esketamine exposure was associated with a higher or lower risk of recorded nonfatal, medically attended suicide attempt or intentional self-harm among adults with...
Cureus
September 2026
Hemachandran Ravikumar, Suresh Sathyanarayanan
Background Psychological stress contributes to mental health symptoms and cardiovascular risk through pathways involving anxiety, depression, cortisol secretion, autonomic dysregulation, and elevated blood pressure. Sound-based meditation is a nonpharmacological approach that may support stress management, but randomized controlled trial evidence remains limited. Objective The objective was to...
Journal of managed care & specialty pharmacy
September 2026
Bridget Flavin, Gary Small, Charles Dragovich et al.
Treatment-resistant depression (TRD) is a subset of major depressive disorder (MDD) most commonly defined as failure to respond to 2 or more antidepressant regimens despite adequate dose, duration, and adherence to treatment. The burden of TRD impacts individuals, families, and society, with outcomes such as decreased health-related quality of life and increased health care utilization and...
The Brown University Psychopharmacology Update
September 1, 2026
A systematic review and meta‐analysis encompassing 26 ran‐domized controlled trials (RCTs) has concluded that both single and repeated infusions of ketamine significantly improve suicidality and depressive symptoms in patients with a major depressive episode. Most of the serious adverse events that were reported in the included trials were determined to be unrelated to study treatment.
International Journal of Innovative Technologies in Social Science
August 31, 2026
Anna Szeszko, Weronika Maria Czernek, Magdalena Cichorzewska et al.
Psychedelic-assisted therapy has emerged as a prominent area for psychiatric investigation particularly with regards to treatment-resistant depression and Post Traumatic Stress Disorder (PTSD). The purpose of this narrative review was to outline the current body of research regarding psychedelic and psychedelic-like compounds in these two psychiatric conditions highlighting psilocybin-assisted...
Bipolar Disorders
August 30, 2026
Chih‐Cheng Lin, Lien‐chung Wei
OBJECTIVES: To contextualize the real-world findings of repeated intravenous ketamine infusions for treatment-resistant bipolar depression (TRBPD) and identify priorities for safer, more durable clinical implementation. METHODS: We provide a focused commentary on Zhou et al. (2023) and integrate selected evidence concerning inflammatory and metabolic correlates, neurocognitive outcomes, and...
Eur Arch Psychiatry Clin Neurosci
August 29, 2026
Esketamine-based treatment, depression-specific metacognitive training, and their combination in treatment-resistant depression: 6-month trajectories of depressive symptoms and rumination in a multicenter observational study.
Eur J Drug Metab Pharmacokinet
August 28, 2026
Development of a Physiologically Based Pharmacokinetic/Pharmacodynamic Model of Psilocybin/Psilocin from Psilocybe cubensis (Magic Mushroom) in Treatment-Resistant Depression.
Zenodo (CERN European Organization for Nuclear Research)
August 27, 2026
D. Dilhani Indrachapa
The rapid development of technical power and globalization in the twenty first century have enabled mankind to enjoy unprecedented material comforts but at the same time have presented him with complex social and psychological problems. Young people are experiencing significant mental health issues, mainly stress and depression, in a very competitive society today. This paper investigates...
The New England journal of medicine
November 3, 2022
Guy M. Goodwin, Scott T Aaronson, Oscar Alvarez et al.
1,095 citations
Psilocybin is being studied for use in treatment-resistant depression. In this phase 2 double-blind trial, we randomly assigned adults with treatment-resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a dose of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary end point was the change from baseline to week 3 in the...
New England Journal of Medicine
April 14, 2021
Robin Carhart-Harris, Bruna Giribaldi, Rosalind Watts et al.
1,372 citations
On the basis of the change in depression scores on the QIDS-SR-16 at week 6, this trial did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Secondary outcomes generally favored psilocybin over escitalopram, but the analyses of these outcomes lacked correction for multiple comparisons. Larger and longer trials are...
JAMA Psychiatry
November 4, 2020
Mary P Cosimano, Alan K. Davis, Frederick S. Barrett et al.
1,269 citations
Importance: Major depressive disorder (MDD) is a substantial public health burden, but current treatments have limited effectiveness and adherence. Recent evidence suggests that 1 or 2 administrations of psilocybin with psychological support produces antidepressant effects in patients with cancer and in those with treatment-resistant depression. Objective: To investigate the effect of...
Psychopharmacology (Berl)
November 8, 2017
R. L. Carhart-Harris, Mark Bolstridge, C. M. J. Day et al.
978 citations
RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major...
Journal of Psychopharmacology
November 30, 2016
Stephen Ross, Anthony P. Bossis, Jeffrey Guss et al.
1,699 citations
Background: Clinically significant anxiety and depression are common in patients with cancer, and are associated with poor psychiatric and medical outcomes. Historical and recent research suggests a role for psilocybin to treat cancer-related anxiety and depression. Methods: In this double-blind, placebo-controlled, crossover trial, 29 patients with cancer-related anxiety and depression were...
Journal of Psychopharmacology
November 30, 2016
Annie Umbricht, Mary P Cosimano, Roland R. Griffiths et al.
2,174 citations
Cancer patients often develop chronic, clinically significant symptoms of depression and anxiety. Previous studies suggest that psilocybin may decrease depression and anxiety in cancer patients. The effects of psilocybin were studied in 51 cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety. This randomized, double-blind, cross-over trial investigated the...
Lancet Psychiatry
May 17, 2016
Robin Carhart-Harris, Mark Bolstridge, James Rucker et al.
1,546 citations
BACKGROUND: Psilocybin is a serotonin receptor agonist that occurs naturally in some mushroom species. Recent studies have assessed the therapeutic potential of psilocybin for various conditions, including end-of-life anxiety, obsessive-compulsive disorder, and smoking and alcohol dependence, with promising preliminary results. Here, we aimed to investigate the feasibility, safety, and efficacy...
American Journal of Psychiatry
August 28, 2013
James W. Murrough, Dan V. Iosifescu, Lee C. Chang et al.
1,207 citations
OBJECTIVE: Ketamine, a glutamate N-methyl-d-aspartate (NMDA) receptor antagonist, has shown rapid antidepressant effects, but small study groups and inadequate control conditions in prior studies have precluded a definitive conclusion. The authors evaluated the rapid antidepressant efficacy of ketamine in a large group of patients with treatment-resistant major depression. METHOD: This was a...
Science
October 4, 2012
Ronald S. Duman, George K. Aghajanian
1,613 citations
Basic and clinical studies demonstrate that depression is associated with reduced size of brain regions that regulate mood and cognition, including the prefrontal cortex and the hippocampus, and decreased neuronal synapses in these areas. Antidepressants can block or reverse these neuronal deficits, although typical antidepressants have limited efficacy and delayed response times of weeks to...
Archives of General Psychiatry
August 1, 2010
Nancy Diazgranados, Lobna Ibrahim, Nancy E. Brutsché et al.
969 citations
CONTEXT: Existing therapies for bipolar depression have a considerable lag of onset of action. Pharmacological strategies that produce rapid antidepressant effects-for instance, within a few hours or days-would have an enormous impact on patient care and public health. OBJECTIVE: To determine whether an N-methyl-D-aspartate-receptor antagonist produces rapid antidepressant effects in subjects...
August 21, 2006
1,332 citations
In this chapter I will describe how Mark Williams, Zindel Segal, and I developed a novel, theory-driven, psychological intervention to reduce relapse in recurrent major depression. The intervention, mindfulness-based cognitive therapy (MBCT) incorporates, as a central component, mindfulness training. We drew heavily on the mindfulness-based stress reduction (MBSR) program developed by Jon...
Archives of General Psychiatry
August 1, 2006
Carlos A. Zarate, Jaskaran Singh, Paul J. Carlson et al.
3,762 citations
CONTEXT: Existing therapies for major depression have a lag of onset of action of several weeks, resulting in considerable morbidity. Exploring pharmacological strategies that have rapid onset of antidepressant effects within a few days and that are sustained would have an enormous impact on patient care. Converging lines of evidence suggest the role of the glutamatergic system in the...
Journal of Consulting and Clinical Psychology
2004
S. Helen Ma, John D. Teasdale
1,401 citations
Recovered recurrently depressed patients were randomized to treatment as usual (TAU) or TAU plus mindfulness-based cognitive therapy (MBCT). Replicating previous findings, MBCT reduced relapse from 78% to 36% in 55 patients with 3 or more previous episodes; but in 18 patients with only 2 (recent) episodes corresponding figures were 20% and 50%. MBCT was most effective in preventing relapses not...
Psychotherapy Research
March 1, 2003
D. Morgan
1,203 citations
(2003). Mindfulness-Based Cognitive Therapy for Depression: A New Approach to Preventing Relapse. Psychotherapy Research: Vol. 13, No. 1, pp. 123-125.